Virtus Lifesci Biotech Clinical Trials ETF (BBC)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Phone: (212) 593-4383
macroaxis
macroaxis May. 23 at 5:10 AM
$BBC - Implied volatility is shrinking to 0.56 for Virtus LifeSci https://www.macroaxis.com/stock-options/BBC/Virtus-LifeSci-Biotech?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
NorthShoreTrader2021
NorthShoreTrader2021 May. 12 at 2:17 AM
$LABU It is down 3% overnight on robinhood. $IBB, $XBI, $BBC
0 · Reply
geroscience
geroscience May. 7 at 8:40 AM
$LCTX $XBI $BBC Thoughts on new FDA CBER head Vinay Prasad: Having read many of his papers/watched his YT over the years, if he is to be consistent with his beliefs then this will be bearish for biotech as a sector, consistent with the market selloff today. He is against surrogate endpoints (in absence of clinically relevant functional benefit shown in adequately powered trials) and strongly errs on the side of primum non nocere 'do no harm', even if this means one delays approval of a *potentially* beneficial drug. The counterargument to this is that cancer patients may die waiting for a drug that could have been effective - the problem with this, and I am sympathetic to Vinay's view, is that most investigational cancer drugs fail to improve survival and/or are toxic, so delaying approval for more robust pivotal trial evidence is net good for society (and taxpayers). However, biotechs relying on accelerated approval will be hampered (simply consider how NPV changes w/ delayed revs).
1 · Reply
Pika_Capital
Pika_Capital Apr. 21 at 2:21 PM
$XBI $BBC you are about to miss the biggest bull market in biotech history from these depressed 💀 levels
1 · Reply
frontiere
frontiere Apr. 11 at 9:46 AM
$ONVO Organovo — bought lows sold yesterday below $3 unfortunately, rebuying now — spike from $2 to $3.6 (low-ish volume, albeit) was also due to this FDA new plan phasing out animal studies? 👇Due to Organovo’s organoid sold to LLY? Btw + FDA roadmap attached to that PR https://www.fda.gov/media/186092/download : 👍 gives more color on the challenges (low predictivity and high NHP cost) and the alternative methods. 👍openness to new tools & models while maintaining the integrity. It guides more on the "reduce and refine" (e.g. 3-month GLP tox + NAMs), less on "replace". 👍GLP tox (dog & primate) is one of key milestones in preclinical dev. The blocker from NHP cost as well as availability seems to be what triggered this roadmap. The trade war made it much worse. $XBI $XLV $BBC DNA CERT SLP SDGR CRL
1 · Reply
TwoThirdsProbablyDown
TwoThirdsProbablyDown Apr. 4 at 2:49 PM
$SGMO in line with $BBC etfs that track clinical stage biotechs, but still annoying as hell. SP (high or low) remains arbitrary until we see terms of Fabry deal. I’m wondering if that stupid Barclays event for the quarter had the sole purpose of messaging to potl Fabry partners that SM was going to do Capsid deals and not cave to their hardball tactics.
1 · Reply
precise
precise Apr. 1 at 6:00 PM
$XBI $BBC Clinical bios hit this low 4x in the past 10 years and average returns thereafter of 69% in 2.87 months
2 · Reply
ComradeKomisar
ComradeKomisar Mar. 31 at 8:35 PM
$EBS v $BBC EBS is trading sub-clinically LMAO since earnings, and clinically since Feb 18. The market thinks we have no products, no pipe, no revenue.
2 · Reply
alexpitti
alexpitti Mar. 26 at 11:04 PM
every day is a new beat down $XBI $BBC
0 · Reply
AlphaTuna
AlphaTuna Mar. 20 at 10:40 PM
Highest Volume Rated ETFs Per 3/20/2025’s Close: 1 – $PSMR 2 – $MYCL 3 – $MYCM 4 – $MYCK 5 – $MYCN 6 – $XBJL 7 – $KURE 8 – $TJUL 9 – $LLDR 10 – $BBC https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-3-20-2025/
0 · Reply
Latest News on BBC
Healthcare Sector Checkup As U.S. Looks To Change Regulations

May 30, 2025, 3:30 PM EDT - 25 days ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBH BBP BIB BIS BMED

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Feb 25, 2025, 11:06 AM EST - 4 months ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

IBB XLV AGNG ARKG BBH BBP BIB

The Fall Of SVB: What It Means For Healthcare Startups

Mar 16, 2023, 3:51 PM EDT - 2 years ago

The Fall Of SVB: What It Means For Healthcare Startups

BBH FBT IBB IHE IHF IHI IYH

Can Health Care Stocks Outperform Again In 2023?

Jan 11, 2023, 6:09 PM EST - 2 years ago

Can Health Care Stocks Outperform Again In 2023?

AGNG ARKG BBH BBP BMED CNCR FBT

What The Inflation Reduction Act Means For Drug Prices

Aug 26, 2022, 1:24 AM EDT - 3 years ago

What The Inflation Reduction Act Means For Drug Prices

BBH IBB IHE IHF IHI IYH PBE

Should Investors Follow Private Equity into Life Sciences?

Aug 19, 2021, 7:51 PM EDT - 4 years ago

Should Investors Follow Private Equity into Life Sciences?

BNTX CNCR PFE

Biotechs Ready To Roar

Jun 10, 2021, 9:30 AM EDT - 4 years ago

Biotechs Ready To Roar

ANVS ARVN AVXL BBH BBP BHVN BIIB

Moving Beyond COVID In Biopharma

Apr 15, 2021, 9:31 AM EDT - 4 years ago

Moving Beyond COVID In Biopharma

BBH BBP CNCR FBT FTXH GNOM HQL

Novavax's 30% surge boosts biotech ETFs to best day in weeks

Jul 7, 2020, 12:22 PM EDT - 5 years ago

Novavax's 30% surge boosts biotech ETFs to best day in weeks

NVAX

3 ETFs With Q2 Gains Of At Least 30%

Jun 30, 2020, 3:46 PM EDT - 5 years ago

3 ETFs With Q2 Gains Of At Least 30%

ACES ARGT

The Market Speaks: 3 Mega Trends Are Happening

Jun 6, 2020, 3:19 AM EDT - 5 years ago

The Market Speaks: 3 Mega Trends Are Happening

AMT BOTZ CCI ROBO SBAC

3 Biotech ETFs Up 10% Or More Over The Last Month

May 7, 2020, 11:36 AM EDT - 5 years ago

3 Biotech ETFs Up 10% Or More Over The Last Month

ARKG

Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be

Mar 10, 2020, 5:47 PM EDT - 5 years ago

Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be

Best Growth ETFs for Q1 2020

Feb 13, 2020, 9:19 AM EST - 5 years ago

Best Growth ETFs for Q1 2020

VGT XLK

Best Healthcare ETFs for Q1 2020

Feb 10, 2020, 1:40 PM EST - 5 years ago

Best Healthcare ETFs for Q1 2020

KURE SBIO

5 Best ETFs Of 2019

Dec 28, 2019, 6:02 PM EST - 5 years ago

5 Best ETFs Of 2019

GOAU PALL TAN XSD

There's A Really Good Chance You Missed One Of The Year's Best ETFs

Dec 9, 2019, 7:25 AM EST - 6 years ago

There's A Really Good Chance You Missed One Of The Year's Best ETFs

macroaxis
macroaxis May. 23 at 5:10 AM
$BBC - Implied volatility is shrinking to 0.56 for Virtus LifeSci https://www.macroaxis.com/stock-options/BBC/Virtus-LifeSci-Biotech?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
NorthShoreTrader2021
NorthShoreTrader2021 May. 12 at 2:17 AM
$LABU It is down 3% overnight on robinhood. $IBB, $XBI, $BBC
0 · Reply
geroscience
geroscience May. 7 at 8:40 AM
$LCTX $XBI $BBC Thoughts on new FDA CBER head Vinay Prasad: Having read many of his papers/watched his YT over the years, if he is to be consistent with his beliefs then this will be bearish for biotech as a sector, consistent with the market selloff today. He is against surrogate endpoints (in absence of clinically relevant functional benefit shown in adequately powered trials) and strongly errs on the side of primum non nocere 'do no harm', even if this means one delays approval of a *potentially* beneficial drug. The counterargument to this is that cancer patients may die waiting for a drug that could have been effective - the problem with this, and I am sympathetic to Vinay's view, is that most investigational cancer drugs fail to improve survival and/or are toxic, so delaying approval for more robust pivotal trial evidence is net good for society (and taxpayers). However, biotechs relying on accelerated approval will be hampered (simply consider how NPV changes w/ delayed revs).
1 · Reply
Pika_Capital
Pika_Capital Apr. 21 at 2:21 PM
$XBI $BBC you are about to miss the biggest bull market in biotech history from these depressed 💀 levels
1 · Reply
frontiere
frontiere Apr. 11 at 9:46 AM
$ONVO Organovo — bought lows sold yesterday below $3 unfortunately, rebuying now — spike from $2 to $3.6 (low-ish volume, albeit) was also due to this FDA new plan phasing out animal studies? 👇Due to Organovo’s organoid sold to LLY? Btw + FDA roadmap attached to that PR https://www.fda.gov/media/186092/download : 👍 gives more color on the challenges (low predictivity and high NHP cost) and the alternative methods. 👍openness to new tools & models while maintaining the integrity. It guides more on the "reduce and refine" (e.g. 3-month GLP tox + NAMs), less on "replace". 👍GLP tox (dog & primate) is one of key milestones in preclinical dev. The blocker from NHP cost as well as availability seems to be what triggered this roadmap. The trade war made it much worse. $XBI $XLV $BBC DNA CERT SLP SDGR CRL
1 · Reply
TwoThirdsProbablyDown
TwoThirdsProbablyDown Apr. 4 at 2:49 PM
$SGMO in line with $BBC etfs that track clinical stage biotechs, but still annoying as hell. SP (high or low) remains arbitrary until we see terms of Fabry deal. I’m wondering if that stupid Barclays event for the quarter had the sole purpose of messaging to potl Fabry partners that SM was going to do Capsid deals and not cave to their hardball tactics.
1 · Reply
precise
precise Apr. 1 at 6:00 PM
$XBI $BBC Clinical bios hit this low 4x in the past 10 years and average returns thereafter of 69% in 2.87 months
2 · Reply
ComradeKomisar
ComradeKomisar Mar. 31 at 8:35 PM
$EBS v $BBC EBS is trading sub-clinically LMAO since earnings, and clinically since Feb 18. The market thinks we have no products, no pipe, no revenue.
2 · Reply
alexpitti
alexpitti Mar. 26 at 11:04 PM
every day is a new beat down $XBI $BBC
0 · Reply
AlphaTuna
AlphaTuna Mar. 20 at 10:40 PM
Highest Volume Rated ETFs Per 3/20/2025’s Close: 1 – $PSMR 2 – $MYCL 3 – $MYCM 4 – $MYCK 5 – $MYCN 6 – $XBJL 7 – $KURE 8 – $TJUL 9 – $LLDR 10 – $BBC https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-3-20-2025/
0 · Reply
alexpitti
alexpitti Mar. 11 at 1:04 AM
It's really crazy how much $BBC has fallen since November considering how much rates have fallen $XBI $ABEO $LRMR
1 · Reply
alexpitti
alexpitti Mar. 4 at 2:53 AM
Imagine if $BBC didn't decline every day
0 · Reply
Reanimated666
Reanimated666 Feb. 14 at 8:30 PM
$BBC $RXRX position
0 · Reply
50bps
50bps Jan. 10 at 10:50 PM
$BBC nasty
0 · Reply
ItsABull_Market
ItsABull_Market Sep. 25 at 3:35 PM
$SPY $XBI $IBB $BBC I know that this is about Universities and research institutes, BUT... "One paper has been cited 1163 times, except it DOES NOT EXIST. This 'paper' was used in a style guide as a citation example, was included in some papers by accident, and then propagated from there, illustrating how some authors don't read *titles* let alone abstracts or papers"
1 · Reply
TalkMarkets
TalkMarkets Jul. 12 at 6:17 PM
#Inflation Cools In June, Triggers Spike In Laggard #ETFs $ITB $IWC $KRE $PBW $BBC https://talkmarkets.com/content/etfs/inflation-cools-in-june-triggers-spike-in-laggard-etfs?post=454103
0 · Reply
AlmostCanadianTrader
AlmostCanadianTrader May. 13 at 12:36 PM
$RILY r/WallStreetBets mods trying to shutdown the$GME conversation just like they shutdown $RILY . Seems really really sus they are picking and choosing the stocks they let get pumped ($DJT $CUK $BBC). Maybe someone should investigate why they are intentionally manipulating the board.
2 · Reply